Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.

Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 23;13:3485-3492. doi: 10.2147/COPD.S173664. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2018 Dec 05;13:3899.

2.

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.

Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.

Int J Chron Obstruct Pulmon Dis. 2012;7:201-9. doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.

3.

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K.

Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:889-904. doi: 10.2147/COPD.S62750. eCollection 2014.

4.

Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.

Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM.

Int J Chron Obstruct Pulmon Dis. 2015 May 13;10:925-37. doi: 10.2147/COPD.S82064. eCollection 2015.

5.

2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group.

Högman M, Sulku J, Ställberg B, Janson C, Bröms K, Hedenström H, Lisspers K, Malinovschi A.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 3;13:165-173. doi: 10.2147/COPD.S151016. eCollection 2018.

6.
7.

A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.

Ding B, Small M, Holmgren U.

Int J Chron Obstruct Pulmon Dis. 2017 May 23;12:1527-1537. doi: 10.2147/COPD.S133793. eCollection 2017.

9.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

10.

Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.

Ke X, Marvel J, Yu TC, Wertz D, Geremakis C, Wang L, Stephenson JJ, Mannino DM.

Int J Chron Obstruct Pulmon Dis. 2016 Jul 27;11:1689-703. doi: 10.2147/COPD.S108967. eCollection 2016.

11.

Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status.

de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martín-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V, Gil de MA, Jimenez-Garcia R.

Lung. 2011 Jun;189(3):199-206. doi: 10.1007/s00408-011-9289-0. Epub 2011 Apr 17.

PMID:
21499887
12.

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.

Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 5;13:781-792. doi: 10.2147/COPD.S153655. eCollection 2018.

13.

COPD management costs according to the frequency of COPD exacerbations in UK primary care.

Punekar YS, Shukla A, Müllerova H.

Int J Chron Obstruct Pulmon Dis. 2014;9:65-73. doi: 10.2147/COPD.S54417. Epub 2014 Jan 9. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:247.

14.

Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.

Chalmers JD, Tebboth A, Gayle A, Ternouth A, Ramscar N.

NPJ Prim Care Respir Med. 2017 Jun 29;27(1):43. doi: 10.1038/s41533-017-0040-z.

15.

The pharmacological cost of COPD during Greek economic crisis.

Stafyla E, Kerenidi T, Gerogianni I, Geitona M, Daniil Z, Gourgoulianis KI.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:461-466. doi: 10.2147/COPD.S123095. eCollection 2017.

16.

Initiation of triple therapy maintenance treatment among patients with COPD in the US.

Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 22;12:73-83. doi: 10.2147/COPD.S122013. eCollection 2017.

17.

Symptomatic burden of COPD for patients receiving dual or triple therapy.

Chen S, Small M, Lindner L, Xu X.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 27;13:1365-1376. doi: 10.2147/COPD.S163717. eCollection 2018.

18.

Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial.

Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 3;12:3255-3262. doi: 10.2147/COPD.S142997. eCollection 2017.

19.

Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.

Wurst KE, Shukla A, Muellerova H, Davis KJ.

COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.

PMID:
24945236
20.

Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting.

Miravitlles M, Sicras A, Crespo C, Cuesta M, Brosa M, Galera J, Lahoz R, Lleonart M, Riera MI.

Ther Adv Respir Dis. 2013 Jun;7(3):139-50. doi: 10.1177/1753465813484080. Epub 2013 May 7.

PMID:
23653458

Supplemental Content

Support Center